一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集

Abstract

Full Text of PDF Full Text of PDF (481k)  required ID / password
Article in Japanese

Case Report

A case of pembrolizumab-induced secondary sclerosing cholangitis in a patient with lung adenocarcinoma

Takumi Kanokogia  Muneyuki Sekiyaa  Chiaki Katoa  Takanori Mukozub  Kazutoshi Shibuyac  Kazuma Kishia 

aDepartment of Respiratory Medicine, Toho University Omori Medical Center
bDepartment of Gastroenterology and Hepatology, Toho University Omori Medical Center
cDepartment of Diagnostic Pathology, Toho University Omori Medical Center

ABSTRACT

A 54-year-old man diagnosed with lung adenocarcinoma and receiving combination therapy with pembrolizumab and chemotherapy presented with fever and liver dysfunction. Findings from magnetic resonance cholangiopancreatography and liver biopsy indicated a diagnosis of pembrolizumab-induced secondary sclerosing cholangitis. Although liver function improved during treatment with ursodeoxycholic acid, bezafibrate, and steroid, it worsened during tapering of the steroid. Immune checkpoint inhibitor-induced secondary sclerosing cholangitis is a rare immune-related adverse event that is often difficult to treat.

KEYWORDS

Lung cancer  Sclerosing cholangitis  Immune checkpoint inhibitor (ICI)  Pembrolizumab  Immune-related adverse event 

Received 29 Sep 2021 / Accepted 3 Dec 2021

AJRS, 11(2): 92-97, 2022

Google Scholar